Showing 181 - 200 results of 293 for search '(( 6 14 decrease ) OR ( 10 ((teer decrease) OR (((nn decrease) OR (mean decrease)))) ))*', query time: 0.16s Refine Results
  1. 181
  2. 182
  3. 183
  4. 184
  5. 185

    Dynamic stretching alone can impair slower velocity isokinetic performance of young male handball players for at least 24 hours by Haddad, Monoem

    Published 2019
    “…Two-way repeated measures ANOVAs revealed that 1) both the SS and control conditions exhibited knee extensor 60.s -1 (SS:-10.3%; p = 0.04, Control: -8.7%; p = 0.07) and 300.s -1 (SS: -12.9%; p = 0.005, Control: -16.3%; p = 0.02) isokinetic deficits at post-test, 2) DS impaired knee flexor 60.s -1 isokinetic work and power-related measures at post-test (Work: -10.1%; p = 0.0006; Power: -19.1%; p = 0.08) and at 24-hours' post-test (Work: 9.9%; p = 0.023; Power: -9.6%; p = 0.01), 3) DS (12.07% and 10.47%) and SS (13.7% and 14.6%) enhanced knee flexor 300.s -1 isokinetic force and power-related measures compared to control. …”
    Get full text
    Get full text
  6. 186
  7. 187
  8. 188
  9. 189
  10. 190
  11. 191
  12. 192
  13. 193

    The Expression of TBC1 Domain Family, Member 4 (TBC1D4) in Skeletal Muscles of Insulin-Resistant Mice in Response to Sulforaphane by Rizk, Nasser M

    Published 2020
    “…Results: SFN-treated DIO mice had significantly lower non-fasting blood glucose levels than vehicle-treated mice (194.16 ± 14.12 vs. 147.44 ± 20.31 mg/dL, vehicle vs. SFN, p value=0.0003). …”
    Get full text
    Get full text
  14. 194
  15. 195
  16. 196
  17. 197
  18. 198

    The Cardiovascular Benefits of Empagliflozin, A Sodium Glucose Cotransporter Inhibitor: Is NHE1 a Viable Target? by Al-Shamasi, Al-Anood

    Published 2020
    “…In this trial, treatment with EMPA over 2.6 years decreased cardiovascular vascular events (14% reduction). …”
    Get full text
    Get full text
  19. 199
  20. 200